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mobilization from thapsigargin-sensitive intracellular stores, whereas 15d-PGJ2 (5 M) did not induce any Ca 2ϩ signal. The PPAR␥ antagonist GW-9662 did not inhibit any biological responses, but it reversed the effect of 15d-PGJ 2 on cell growth. Using RT-PCR, we detected mRNA expression of the GPR40 receptor, a G proteincoupled receptor recently identified as a receptor for free fatty acids and TZDs, in human bronchial epithelial cells. Downregulation of GPR40 by small-interfering RNA led to a significant inhibition of TZD-induced Ca 2ϩ mobilization and proliferation. This study provides evidence for the proliferative effect of anti-diabetic drug TZDs in nonmalignant human bronchial epithelial cells through GPR40 receptor activation, involving an intracellular Ca 2ϩ signaling pathway. airway epithelium; glitazone; calcium; peroxisome proliferator-activated receptor-␥; G protein receptor 40 THIAZOLIDINEDIONES (TZDs), such as troglitazone (TGZ), rosiglitazone (RGZ), pioglitazone (PGZ), and ciglitazone (CGZ), are synthetic compounds used in the treatment of type II diabetes to improve insulin sensitivity and reduce blood glucose and triglyceride levels (28, 40) . TZDs are selective ligands for a nuclear hormone receptor known as peroxisome proliferator-activated receptor-␥ (PPAR␥), a member of the PPAR family. The four PPAR isoforms that have been identified to date (␣, ␤, ␦, and ␥) display different tissue distribution and function (21) . In addition to the synthetic anti-diabetic TZDs, some endogenous mediators, including the cyclopentenone prostaglandin 15-deoxy-⌬ 12,14 prostaglandin J 2 (15d-PGJ 2 ), some polyunsaturated fatty acids, and eicosanoids, bind and activate PPAR␥ (17, 23) . Activation of PPAR␥ results in heterodimerization of the receptor with the retinoid X receptor and binding to specific peroxisome proliferator-responsive elements located within the promoter region of target genes involved in lipid biosynthesis and glucose homeostasis. PPAR␥ is highly expressed in the liver, kidney, intestinal mucosa, and in adipose tissue where it plays a critical role in adipocyte differentiation (15) . PPAR␥ is also expressed in numerous cell types, including epithelial cells of the breast, colon, ovary, and lung (26, 39) . Anti-inflammatory properties have been described for PPAR␥ ligands (34) . In addition, anti-tumorigenic actions for TZDs have been reported. A number of in vitro and in vivo studies showed that PPAR␥ ligands inhibited growth of many cancer cell types, including colon (2, 32) , breast (14) , prostate (25) , and lung (7, 10, 22) .
Over the last few years, an increasing number of studies reported that TZDs are able to exert some PPAR␥-independent actions (16) . The best direct evidence comes from receptor knockout studies where TZDs inhibited tumor growth in both PPAR␥ ϩ/ϩ and PPAR␥ Ϫ/Ϫ mouse embryonic stem cells (29) . Moreover, in several studies, the rapid occurrence of TZDinduced effects (within min to h) suggested that TZDs may have some PPAR␥-independent actions that are rather characteristic of cell surface receptor involvement. Recently, a subfamily of deorphanized homologous G protein-coupled receptors (GPCRs) which is activated by saturated and unsaturated long-chain fatty acids, was identified (9) . Among them, the GPR40 receptor is described to be specifically activated by free fatty acids and TZDs (9, 20, 24) . GPR40 is highly expressed in the brain and pancreatic ␤-cells and to a lesser extent in other tissues (9) . Interestingly, GPR40 is expressed in the lung, but its physiological role in airways is still unknown.
The role of TZDs in lung cancer has been studied in vitro using cancer cell lines and in animal models. However, effect of TZDs on normal human bronchial epithelial cells (HBEC) has not been investigated. In this study, we report for the first time that both TGZ and RGZ induced proliferation of nonmalignant HBEC via Ca 2ϩ mobilization, whereas the non-TZD PPAR␥ ligand 15d-PGJ 2 inhibited cell growth. These unexpected effects of TZDs were independent of PPAR␥ and were mediated by the G protein-coupled GPR40 receptor. These data provide novel mechanisms for TZD actions in nonmalignant airway epithelial cells.
MATERIALS AND METHODS
Materials. 15d-PGJ2, RGZ, TGZ and GW-9508 were purchased from Cayman Chemical (Ann Arbor, MI). GW-9662 was obtained from Merck Biosciences (Fontenay sous-bois, France). Thapsigargin was purchased from Sigma-Aldrich (St-Quentin-Fallavier, France).
Cell culture. The immortalized HBEC line BEAS-2B and human alveolar adenocarcinoma A549 cell line were obtained from ATCC (Rockville, MD). They were cultured in RPMI medium supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, and 10% FCS. Primary culture of small airway epithelial cells (SAEC; CloneticsBioWhittaker, San Diego, CA) were maintained as previously described (5) .
Proliferation assay. Cell proliferation was determined using the reduction of tetrazolium dye (MTT; Chemicon, Temecula, CA) to blue formazan, which measures living cells. Cells (5 ϫ 10 3 cells ⅐ 100 l Ϫ1 ⅐ well Ϫ1 ) were seeded in 96-well plates and incubated overnight in serum-free medium. Cells were then incubated with RGZ (1-30 M), TGZ (0.1-10 M), 15d-PGJ 2 (5 M), or 10% FCS (used as positive control) or vehicle (medium 2% FCS). When PPAR␥ antagonist was used, cells were pretreated for 30 min with the antagonist before stimulation with TZDs or 15d-PGJ 2. MTT solution (10 l) was then added to each well and incubated for 4 h (37°C). Dye was extracted from cells with 100 l of isopropanol-1 N HCl (96:4, vol/vol), and absorbance at 570 nm was determined. A linear relationship was determined for MTT reduction (absorbance at 570 nM) and BEAS-2B cell number [y ϭ 10 Ϫ(5x ϩ 0,0995) , r 2 ϭ 0, 98]. Cell cycle analysis. BEAS-2B cells were plated in six-well plates and were serum starved for 24 h. Cells were then treated with or without RGZ (10 M) for 24 h in medium containing 0.5% FCS. Medium containing 10% FCS was used as a positive control. Cells were then removed with trypsin-EDTA solution and were fixed by mixing 1 ml PBS with 6 ml cold 100% methanol and kept at Ϫ20°C. After removal of methanol, cells were treated with the Coulter DNA-Prep reagents kit (Beckman Coulter, Villepinte, France). Cells were resuspended in 50 l lysing and permeabilizing reagent and 200 l propidium iodide solution containing RNase. Flow cytometry analyses were performed using a FACSCalibur flow cytometer (BectonDickinson, le Pont de Claix, France). The red DNA fluorescence signal was analyzed as pulse width vs. area to eliminate doublets and aggregates. FL2 area histogram has been drawn and formatted to assess events of single cells only in a specific gate. Cell cycle distribution was analyzed with the Cell Quest software (BectonDickinson). Data were recorded for at least 10,000 events. Proliferation index [PI ϭ (S ϩ G2M)/(G0G1 ϩ S ϩ G2M) ϫ 100%] was used to determine cell proliferation.
Calcium imaging. The intracellular Ca 2ϩ concentration ([Ca 2ϩ ]i) was measured in BEAS-2B cells or A549 cells according to the method previously described (6) . Cells were grown on glass bottom dishes (WPI, Stevenage, UK). Nonconfluent cell monolayers (2 days after plating) were loaded with 25 g/ml Ca 2ϩ -sensitive fluorescent probe fura 2-AM for 45 min, in the dark, at room temperature and were then washed two times in HEPES-buffered Krebs-Henseleit solution (140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, pH 7.4, 280 -290 mosmol/l). The cell preparation was mounted on the stage of an inverted microscope equipped for epifluorescence (TE-300; Nikon, Badhoeve Dorp, Netherlands). Calcium cellular imaging was performed using the Metafluor Imaging System (Universal Imaging). Cell excitation was performed alternatively at 340 and 380 nm using the Optoscan monochromator (Cairn Research, Kent, UK). The emission fluorescence, which is proportional to the level of [Ca 2ϩ ]i, was filtered at 510 nm. The transmitted light image was detected using a Photometrics CoolSNAP-fx video camera (Roper Scientific, Evry, France) coupled to the microscope.
RT-PCR. Total RNA were purified from cell lysates (RNeasy; Qiagen, Valencia, CA), and cDNA were synthesized (Ready-to-Go RT-PCR beads; Amersham, Piscataway, NJ). Semiquantitative human GPR40 gene expression was determined using specific primers (sense primer, 5Ј-GTG TCA CCT GGG TCT GGT CT-3Ј and antisense primer, 5Ј-GAG CAG GAG AGA GAG GCT GA-3Ј).
Western blot. After specific stimulation, whole cells were lysed in 1% Triton X-100, 1 M phenylmethylsulfonyl fluoride, 100 M sodium orthovanadate, and 1:100 protease inhibitor mixtures (SigmaAldrich). Total proteins (30 g) were subjected to SDS-PAGE on 12% Tris ⅐ HCl gels and then transferred to nitrocellulose membranes. Blots were probed with an anti-GPR40 rabbit polyclonal antibody (4°C, overnight, 1:200 dilution) (Tebu-bio, le Perray en Yvelines, France). Next, membranes were incubated with horseradish peroxidase-conjugated goat anti-rabbit antibody (37°C, 1 h, 1:10,000 dilution; Sigma-Aldrich). The monoclonal antibody against ␤-actin (SigmaAldrich) was used as an internal control to show equal protein loading. Visualization was performed by chemiluminescence followed by autoradiography. The density of bands was analyzed using a monochrome CCD camera (RS-170; COHU, San Diego, CA) coupled to the NIH Image analysis program (Pierce Biotechnology, Rockford, IL).
Small-interfering RNA experiments. A pool of four small-interfering RNA (siRNA) 21-mers matching the human GPR40 sequence was provided pooled from Dharmacon Research (Chicago, IL). To detect off-target effects, a mixture of four siRNA constructs harboring at least four mismatches with known human genes (siControl NonTargeting siRNA Pool; Dharmacon Research) was used as a negative control siRNA. Transfection of siRNA with a final concentration of 100 nM was accomplished with ExGen 500 (Euromedex, Mundolsheim, France). After transfection (3 days), GPR40 protein expression was determined, and cells were used for Ca 2ϩ or proliferation assays. Statistical analysis. Values are expressed as means of three experiments on n cells (Ca 2ϩ imaging) Ϯ SE. Comparison among groups was performed using ANOVA for unpaired (Ca 2ϩ experiments) or paired data followed by a Fisher's protected least-significant difference test. For all analyses, findings were considered significant at P Ͻ 0.05.
RESULTS

TZDs induced bronchial epithelial cell proliferation.
To determine the effect of TZDs on cell proliferation, the nonmalignant HBEC line BEAS-2B was treated with RGZ (1, 5, 10, 20, and 30 M) or TGZ (0.1, 1, 5, and 10 M) for 24 h, and proliferation was measured by MTT assay (Fig. 1 ). Both RGZ (Fig. 1A) and TGZ (Fig. 1B) induced a concentration-dependent increase in cell number. The stimulation of cell proliferation by RGZ became significant at a concentration of 5 M and then reached a plateau at 10 M that was sustained for up to 30 M compared with vehicle (n ϭ 5, P Ͻ 0.01) (Fig. 1A) . At the same concentration (10 M), a more pronounced effect on proliferation was observed for TGZ compared with RGZ (3.8 Ϯ 0.1 fold induction vs. 1.9 Ϯ 0.2 fold induction, proliferation fold induction calculated compared with vehicle, n ϭ 5, P Ͻ 0.01). To confirm the proliferative effect of TZDs, we investigated the consequence of 10 M RGZ treatment for 24 h on the different phases of the cell cycle (Fig. 1, C and D) . Quiescent BEAS-2B cells entered S-phase 6 h after RGZ or TGZ stimulation, whereas they entered S-phase 8 h in the presence of 10% FCS (data not shown). At 24 h, the percentage of cells in G 1 /G 0 phase was lower with RGZ stimulation than vehicle (65.6 Ϯ 2.3 vs. 73.7 Ϯ 3.8%, n ϭ 4, P Ͻ 0.05; Fig.  1C ). The percentage of cells in G 2 /M phases after RGZ was significantly higher than vehicle (19.0 Ϯ 0.9 vs. 12.1 Ϯ 3.3, n ϭ 4, P Ͻ 0.05). Moreover, the proliferative index, defined as the total number of cells being in S and G 2 /M phases, was significantly higher in cells stimulated with RGZ than incubated with the vehicle alone (32.4 Ϯ 0.4 vs. 22.5 Ϯ 2.6%, P Ͻ 0.01; Fig. 1D ). All data showed that RGZ and TGZ induced proliferation of nonmalignant HBEC via stimulation of the cell cycle.
RGZ-induced proliferation is independent of PPAR␥.
We next investigated whether the induction of proliferation by TZDs was mediated by the PPAR␥ receptor. First, we tested the effect of the natural PPAR␥ ligand 15d-PGJ 2 on BEAS-2B cell proliferation. Interestingly, 15d-PGJ 2 displayed 45.8 Ϯ 9.5% inhibition of cell proliferation at 24 h compared with vehicle (n ϭ 4, P Ͻ 0.05; Fig. 2A ). In addition, exposure of cells to the selective PPAR␥ antagonist GW-9662 (10 M, 30 min) did not inhibit RGZ-induced proliferation (2.1 Ϯ 0.2 vs. 1.8 Ϯ 0.1, GW-9662 ϩ RGZ compared with RGZ, n ϭ 4; Fig.  2B ). Also, TGZ-induced proliferation was not affected by GW-9662 treatment (data not shown). In contrast, GW-9662 treatment reversed the inhibition of proliferation induced by 15d-PGJ 2 treatment (0.88 Ϯ 0.1 vs. 0.54 Ϯ 0.09, GW-9662 ϩ 15d-PGJ 2 compared with 15d-PGJ 2 , n ϭ 4, P Ͻ 0.05; Fig. 2C ). Taken together, these results demonstrate that RGZ-induced proliferation was independent of PPAR␥, whereas the inhibition of proliferation by 15d-PGJ 2 We next investigated the role of RGZ-induced Ca 2ϩ mobilization on BEAS-2B proliferation. For that purpose, cells were pretreated with thapsigargin (100 nM, 30 min) and then exposed to 10 M RGZ. After 24 h, the proliferation was measured by MTT assay. As shown in Fig. 4C , thapsigargin treatment had no effect on basal BEAS-2B proliferation (1.05 Ϯ 0.28-fold induction, compared with vehicle) but completely attenuated the RGZ proliferative effect (1.1 Ϯ 0.2 vs. 1.8 Ϯ 0.1, thapsigargin ϩ RGZ vs. RGZ, n ϭ 4, P Ͻ 0.05). Also, thapsigargin treatment inhibited TGZ-induced proliferation (data not shown). These last results demonstrate that RGZ-induced Ca 2ϩ increase was involved in the proliferative effect of RGZ on HBEC.
RGZ induced Ca 2ϩ mobilization and proliferation via GPR40 receptor. Recent reports showing the involvement of the human cell surface G protein-coupled receptor GPR40 in rapid responses to TZDs (24) prompted us to investigate if this receptor could be associated with TZD effects observed in our model. Using semiquantitative PCR, we showed that HBEC (SAEC and BEAS-2B) expressed GPR40 mRNA, whereas the adenocarcinoma epithelial cell line A549 did not (Fig. 5A) . We first investigated whether TZDs induce similar biological responses in A549 cells to those observed in HBEC. As shown in cells, 15d-PGJ 2 did not affect Ca 2ϩ in A549 cells (Fig. 5B ) and decreased proliferation in these same cells (Fig. 5C ). To determine whether GPR40 is involved in RGZ-and TGZinduced proliferation in bronchial epithelial cells, we first tested a selective GPR40 agonist (GW-9508) on cell proliferation. As shown in Fig. 6A , GW-9508 induced BEAS-2B proliferation (1.5 Ϯ 0.06-fold induction, n ϭ 3, P Ͻ 0.05), which was abolished by thapsigargin treatment (0.87 Ϯ 0.14-fold induction, n ϭ 3, P Ͻ 0.01). In addition, we performed RNA silencing to reduce endogenous GPR40 mRNA. Transfection of BEAS-2B cells with human GPR40-specific siRNA resulted in a significant decrease of GPR40 protein expression (60% inhibition) compared with control siRNA transfected cells (Fig. 6B) . To know whether RGZ induced a Ca 2ϩ signal in cells via GPR40 receptor in BEAS-2B cells, we performed Ca 2ϩ experiments in cells transfected with GPR40 siRNA. We showed that only 50% of cells transfected with GPR40 siRNA responded to RGZ stimulation, whereas all cells transfected with control siRNA responded to RGZ, probably because of the rate of transfection. Also, in the population of responding cells transfected with GPR40 siRNA, the Ca 2ϩ signal was 50% inhibited compared with cells transfected with control siRNA (P Ͻ 0.01; Fig. 6C ). As shown in Fig. 6C , cell transfection with siRNA affected Ca 2ϩ responses since we showed a 20% decrease in cells transfected with control siRNA compared with nontransfected cells. In addition, the proliferative effect observed with both RGZ and TGZ was almost abrogated in cells transfected with GPR40 siRNA compared with cells transfected with control siRNA (Fig. 6, D and E) . Indeed, RGZ caused a 1.63 Ϯ 0.12-fold induction of proliferation in cells transfected with siRNA control cells and 1.21 Ϯ 0.12-fold induction in cells transfected with GPR40 siRNA (n ϭ 4, P Ͻ 0.05; Fig. 6D ). TGZ induced 2.64 Ϯ 0.21-fold cell proliferation in siRNA control transfected cells and 1.67 Ϯ 0.14-fold in GPR40 siRNA transfected cells (n ϭ 4, P Ͻ 0.01). Moreover, cell cycle experiments showed that the proliferative index, defined as the total number of cells being in S and G 2 /M phases, is decreased significantly after RGZ stimulation in cells transfected by GPR40 siRNA compared with cells transfected with control siRNA (34.86 Ϯ 0.34 vs. 41.67 Ϯ 0.34%, P Ͻ 0.01; Fig. 6E ). These results demonstrated that RGZ-and TGZ-induced Ca 2ϩ release and proliferation were mediated via the recently deorphanized G protein-coupled GPR40 receptor in HBEC.
DISCUSSION
In the present study, we have demonstrated for the first time that both TZDs, RGZ and TGZ, stimulate nonmalignant HBEC proliferation. We demonstrated that this effect was not mediated by the nuclear receptor PPAR␥ but involved the G protein-coupled GPR40 receptor activation, inducing a rapid and transient intracellular Ca 2ϩ mobilization from internal stores. In contrast, the endogenous cyclopentenone prostaglan- PPAR␥ ligands such as TZDs and 15d-PGJ 2 have been described previously as mediators exhibiting anti-tumoral properties, particularly in lung cancer. Indeed, CGZ and 15d-PGJ 2 induced growth arrest of cancer cells through either the induction of apoptosis or the promotion of differentiation (10) . In addition, TGZ and PGZ significantly reduced the number of metastasis and restricted nonsmall cell lung cancer tumor progression in vivo (22) . These inhibitory effects of TZDs on cancerous cell proliferation are related to PPAR␥, and, in patients with lung cancer, a decrease in PPAR␥ expression has been associated with a poorer prognosis (33) . In contrast, in an animal xenograft model, the overexpression of PPAR␥ blocked tumor progression (7). Finally, a retrospective study in a male veteran diabetic population showed a 33% reduction in the diagnosis of lung cancer between TZD users compared with nonusers (18) . Although antiproliferative effects have been described most frequently, PPAR␥ ligands mediate a proliferative effect in mesangial cells (31) , vascular smooth muscle (35) , breast cancer (36), colon cancer (12) and cyclooxygenase-2-depleted cancer cells (13) . In accordance with those previous studies, we demonstrate that TZDs induced proliferation of nonmalignant HBEC. In this study, we used a SV40-transformed bronchial epithelial cell line (BEAS-B cells) that is derived from normal lung to investigate the molecular mechanisms underlying TZD-induced proliferation, but the same findings were observed using primary cultures of SAEC stimulated with TGZ [ Supplemental Fig. S1 (Supplemental data for this article can be found on the American Journal of Physiology: Lung Cellular and Molecular Physiology website.)]. In addition, performing the cell cycle analysis, we confirmed that RGZ and TGZ induced BEAS-2B proliferation with a significant increase in the number of cells entering in S and G 2 /M phases. TZDs exhibited opposite actions on the proliferation of cancerous and normal airway epithelial cells. These results provide evidence for a specific cell type-dependent proliferative action of PPAR␥ ligands.
Within the past few years, PPAR␥-independent effects for TZDs in different cell types and concerning different functions of PPAR␥ ligands have been reported. The evidence for PPAR␥-independent functional effects comes from studies using PPAR␥ null cells. TZDs were able to reduce tumor necrosis factor-␣ and interleukin-6 release induced by interferon-␥ in macrophages derived from PPAR␥ null embryonic stem cells (11) . In addition, TGZ and CGZ inhibited tumor growth in both PPAR␥ Ϫ/Ϫ and PPAR␥ ϩ/ϩ mouse embryonic stem cells (29) . Moreover, PPAR␥ antagonists were unable to block PPAR␥ ligand actions in other studies (1, 30) . In the present study, the cellular proliferation induced by TZDs was independent of PPAR␥, since a PPAR␥ antagonist had no effect. Finally, the rapid occurrence of agonist-induced effects (within min) provides further evidence for a PPAR␥-independent mechanism. Indeed, PPAR␥ ligands were able to activate extracellular signal-regulated protein kinase, which occurred rapidly (within 15 min) in smooth muscle (35) , human colorectal carcinoma (2), and mesangial (38) ] i by intracellular store emptying that is involved in the cell proliferation induced by these compounds. Elevation of [Ca 2ϩ ] i , as induced by TZDs, may be of particular importance in second messenger signaling pathways and in the regulation of cellular proliferation and gene expression (4) .
Recently, TZDs have been reported to bind specifically a membranous GPCR named GPR40 (24) , which is highly expressed in the brain and pancreatic ␤-cells. To a lesser extent, GPR40 is also present in other tissues, including lungs (9) . The role of GPR40 receptor has been well described with regard to insulin secretion from pancreatic ␤-cells (20) , but its physiological role in airways has never been investigated. Our study provides the first demonstration for a physiological role of TZDs via the GPR40 receptor in airway epithelial cells. Previously, it has been shown that GW-9508, a selective GPR40 agonist, induced [Ca 2ϩ ] i mobilization in human embryonic kidney 293 cells expressing GPR40 (8) . In our study, we showed that GW-9508 induced BEAS-2B proliferation that was abolished by thapsigargin treatment. We also reported that GPR40 receptor was expressed in normal HBEC and, siRNAtargeting GPR40 experiments showed that this receptor is potentially involved in TZD-induced Ca 2ϩ signal and proliferation. In addition, in A549 cells, which do not express the GPR40 receptor, TZDs did not induce a Ca 2ϩ signal and cell proliferation. It has been documented previously that activation of the GPR40 receptor by the unsaturated free fatty acid oleate led to a rapid and transient rise in cytosolic Ca 2ϩ and induced proliferation in breast cancer cells (19) .
Hence, our data demonstrated that synthetic (TZDs) and natural PPAR␥ ligands (15d-PGJ 2 ) may use different molecular signaling pathways to mediate their opposite action in nonmalignant HBEC. Indeed, the endogenous PPAR␥ ligand 15d-PGJ 2 inhibited cell growth in both tumoral (A459) and nontumoral (BEAS-2B) cell lines that was reversed by a PPAR␥ antagonist, suggesting a PPAR␥-dependent pathway. Moreover, we did not detect any Ca 2ϩ signal after 15d-PGJ 2 stimulation, emphasizing that TZDs generate other intracellular signals notably via GPR40 activation in nonmalignant HBEC.
In summary, our findings suggest a new potential signaling pathway activated by TZDs in HBEC (Fig. 7) . In nonmalignant HBEC, TZDs may preferentially bind to the G protein-coupled GPR40 receptor, resulting in a rise of [Ca 2ϩ ] i from depletion of internal stores that would promote cell growth. In contrast, the natural prostaglandin 15d-PGJ 2 binds the nuclear receptor PPAR␥ and induces cell growth arrest. Taken together, all of these data provide a novel mechanism of action for TZDs in HBEC stimulating cell proliferation via the GPR40 receptor. Thus GPR40 also plays an important role in the control of cell growth in the lung. Of note, TZDs have been described to have potent anti-inflammatory properties in asthma (3, 27, 37) . Because proliferation is important in the healing process of the injured bronchial epithelium, the present evidence suggests that TZDs may interfere with epithelium remodeling via GPR40 activation. Structural changes of the epithelium are important features of chronic airway disease, mostly refractory to current standard therapies. Therefore, anti-diabetic TZD actions may be interesting to be investigated in these chronic and persistent conditions and may give alternative therapeutic strategy for these respiratory diseases.
